Review
[Parkinson's disease: some physiopathologic aspects and clinical practice]
[Article in
French]
- PMID: 2567050
Item in Clipboard
Review
[Parkinson's disease: some physiopathologic aspects and clinical practice]
[Article in
French]
Rev Prat.
.
Abstract
The lesions of Parkinson's disease chiefly involve the dopaminergic nigrostriatal tract and the great subcortical-cortical dopaminergic, noradrenergic, serotoninergic and cholinergic neuron systems. On the basis of these data, one may suggest a mechanism for some motor and mental disorders, as well as the rationale for treatment with L-dopa, the origin of its main side-effects and the classical escape phenomenon observed with this drug.
Similar articles
-
Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.Mt Sinai J Med. 1988 Jan;55(1):35-42. Mt Sinai J Med. 1988. PMID: 3279303 Review. No abstract available.
-
Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.Brain. 2009 Feb;132(Pt 2):309-18. doi: 10.1093/brain/awn322. Epub 2008 Dec 2. Brain. 2009. PMID: 19050033
-
Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.Ann Neurol. 2000 Apr;47(4 Suppl 1):S115-20; discussion S120-1. Ann Neurol. 2000. PMID: 10762138 Review.
-
Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.Neurosci Biobehav Rev. 2006;30(1):1-23. doi: 10.1016/j.neubiorev.2005.03.024. Epub 2005 Jun 1. Neurosci Biobehav Rev. 2006. PMID: 15935475 Review.
-
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.Behav Brain Res. 2004 May 5;151(1-2):191-9. doi: 10.1016/j.bbr.2003.08.016. Behav Brain Res. 2004. PMID: 15084435
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical